Literature DB >> 12552079

Analysis of common mutations in the galactose-1-phosphate uridyl transferase gene: new assays to increase the sensitivity and specificity of newborn screening for galactosemia.

Steven F Dobrowolski1, Richard A Banas, Joseph G Suzow, Michelle Berkley, Edwin W Naylor.   

Abstract

Classical galactosemia is a genetic disease caused by mutations in the galactose-1-phosphate uridyl transferase (GALT) gene. Prospective newborn screening for galactosemia is routine and utilizes the universally collected newborn dried blood specimen on filter paper. Screening for galactosemia is achieved through analysis of total galactose (galactose and galactose-1-phosphate) and/or determining the activity of the GALT enzyme. While this approach is effective, environmental factors and the high frequency of the Duarte D2 mutation (N314D) does lead to false positive results. Using DNA derived from the original newborn dried blood specimen and Light Cycler technology a panel of five assays able to detect the four most frequently encountered classical galactosemia alleles (Q188R, S135L, K285N, and L195P) and the N314D Duarte variant mutation are described. The five assays are performed simultaneously using common conditions. Including DNA preparation, set-up, amplification, and analysis the genotype data for all five loci is obtained in less than 2 hours. The assays are easily interpreted and amenable to high-throughput newborn screening. Mutational analysis is useful to reduce false positive results, differentiate D/G mixed heterozygotes from classical galactosemia, and to clearly identify a very high percentage of those affected by classical galactosemia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12552079      PMCID: PMC1907369          DOI: 10.1016/S1525-1578(10)60450-3

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  30 in total

1.  Optimization of an automated DNA purification protocol for neonatal screening.

Authors:  E M Heath; D P O'Brien; R Banas; E W Naylor; S Dobrowolski
Journal:  Arch Pathol Lab Med       Date:  1999-12       Impact factor: 5.534

2.  Rapid genotyping of hemochromatosis gene mutations on the LightCycler with fluorescent hybridization probes.

Authors:  K Mangasser-Stephan; C Tag; A Reiser; A M Gressner
Journal:  Clin Chem       Date:  1999-10       Impact factor: 8.327

3.  Molecular heterogeneity of classical and Duarte galactosemia: mutation analysis by denaturing gradient gel electrophoresis.

Authors:  S Greber-Platzer; P Guldberg; S Scheibenreiter; C Item; E Schuller; N Patel; W Strobl
Journal:  Hum Mutat       Date:  1997       Impact factor: 4.878

4.  Integrated amplification and detection of the C677T point mutation in the methylenetetrahydrofolate reductase gene by fluorescence resonance energy transfer and probe melting curves.

Authors:  P S Bernard; M J Lay; C T Wittwer
Journal:  Anal Biochem       Date:  1998-01-01       Impact factor: 3.365

5.  Real-time fluorescence genotyping of factor V Leiden during rapid-cycle PCR.

Authors:  M J Lay; C T Wittwer
Journal:  Clin Chem       Date:  1997-12       Impact factor: 8.327

6.  Neonatal screening for cystic fibrosis in the Trent region (UK): two-stage immunoreactive trypsin screening compared with a three-stage protocol with DNA analysis as an intermediate step.

Authors:  R J Pollitt; A Dalton; S Evans; H N Hughes; D Curtis
Journal:  J Med Screen       Date:  1997       Impact factor: 2.136

7.  The LightCycler: a microvolume multisample fluorimeter with rapid temperature control.

Authors:  C T Wittwer; K M Ririe; R V Andrew; D A David; R A Gundry; U J Balis
Journal:  Biotechniques       Date:  1997-01       Impact factor: 1.993

8.  Newborn screening for cystic fibrosis in Wisconsin: comparison of biochemical and molecular methods.

Authors:  R G Gregg; A Simantel; P M Farrell; R Koscik; M R Kosorok; A Laxova; R Laessig; G Hoffman; D Hassemer; E H Mischler; M Splaingard
Journal:  Pediatrics       Date:  1997-06       Impact factor: 7.124

9.  Mutations in the human biotinidase gene that cause profound biotinidase deficiency in symptomatic children: molecular, biochemical, and clinical analysis.

Authors:  R J Pomponio; J Hymes; T R Reynolds; G A Meyers; K Fleischhauer; G A Buck; B Wolf
Journal:  Pediatr Res       Date:  1997-12       Impact factor: 3.756

10.  A prevalent mutation for galactosemia among black Americans.

Authors:  K Lai; S D Langley; R H Singh; P P Dembure; L N Hjelm; L J Elsas
Journal:  J Pediatr       Date:  1996-01       Impact factor: 4.406

View more
  4 in total

Review 1.  Newborn blood spot screening: new opportunities, old problems.

Authors:  R J Pollitt
Journal:  J Inherit Metab Dis       Date:  2009-05-04       Impact factor: 4.982

2.  Newborn screening for galactosemia in the United States: looking back, looking around, and looking ahead.

Authors:  Brook M Pyhtila; Kelly A Shaw; Samantha E Neumann; Judith L Fridovich-Keil
Journal:  JIMD Rep       Date:  2014-04-10

3.  Clinical, molecular, and genetic evaluation of galactosemia in Turkish children.

Authors:  Sezen Ugan Atik; Semra Gürsoy; Tuba Koçkar; Hasan Önal; Servet Erdal Adal
Journal:  Turk Pediatri Ars       Date:  2016-12-01

4.  Development of DNA confirmatory and high-risk diagnostic testing for newborns using targeted next-generation DNA sequencing.

Authors:  Arindam Bhattacharjee; Tanya Sokolsky; Stacia K Wyman; Martin G Reese; Erik Puffenberger; Kevin Strauss; Holmes Morton; Richard B Parad; Edwin W Naylor
Journal:  Genet Med       Date:  2014-09-25       Impact factor: 8.822

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.